Inflammatory Conditions - Cimzia Drug Quantity Management Policy - Per Days
Defines Cigna's drug quantity limits, one-time override rules, and approval criteria for Cimzia (certolizumab pegol) 200 mg vials and prefilled syringes (including Starter Kit) for inflammatory indications; applies to retail and home delivery supply channels. Approvals are typically for 1 year unless noted; one-time overrides are 30 days.
Policy Statement was updated to clarify that one-time overrides are provided for 30 days in duration.
A note was added clarifying how Starter Kit approval quantity should be calculated (number previously received in past 365 days plus 6 syringes).
Policy updated to reflect existing quantity limits when product obtained via home delivery.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.